BODYCOTE PLC (BOY) — Investment Research Note

Executive summary

Bodycote is the world's largest provider of thermal processing services (heat treatment, HIP, Surface Technology, S3P) for metal components across aerospace, defence, automotive, energy, medical and industrial markets from 131 sites in 22 countries. After two years of revenue decline (2024: -5.7%, 2025: -4.0%) driven by weak Automotive/Industrial and softer Oil & Gas, the group returned to growth in H1 2026 (+3.3% headline, +6.5% organic, +9.6% Core organic) with adjusted operating profit +10.7% and margins +110bps, benefiting from Aerospace/Defence and IGT strength plus the Optimise restructuring programme. The single most important valuation point today is that the stock has re-rated ~45% over the last 12 months and is now trading at roughly fair value — well ahead of the ~680p VWAP of the current buyback programme — leaving thin margin of safety.

Fair value estimate

Methodology: forward multiple of adjusted EPS cross-checked with EV/EBIT.

Key assumptions:

• FY26E adjusted EPS: ~52p (H1 26 delivered 25.2p; H2 comps tougher, guidance is "moderating pace of growth", flat H2 EPS conservative)
• FY27E adjusted EPS: ~58-62p (further Optimise benefits ~£4m incremental, buyback drop-out, normalised variable pay drag ends)
• Fair multiple: 15-18x forward earnings for a scaled, capital-light services leader with mid-single-digit medium-term growth

Fair value range: 850p – 1,050p per share (implied market cap £1,440m – £1,780m)

• vs. current 914.5p / current mcap £1,550m
• Midpoint 950p implies **+4% upside** (essentially fair)
• Low end implies -7%, high end +15%

The Apollo expression of interest disclosed in the H1 2026 filings 2026-07 interim confirms private-market interest exists, but the deal did not progress to a firm offer — suggesting the buyer wasn't willing to pay a meaningful premium to the then-price.

Sector context

Confirmed classification: Industrial Goods and Services (industrial services / specialist metallurgy). Quality profile is above typical for the sector: scale leader with pricing power, low leverage (0.7x net debt/EBITDA), 38-year dividend record, disciplined capital allocation. Growth profile in line with industrials; margin profile above average (16% adj OM). No direct listed peer of the same scale; closest UK-listed comparables include Senior plc (aero/energy engineered components), Melrose (GKN Aerospace), and industrial services names such as Rotork and IMI plc.

Investment thesis (3 bullets)

• Optimise/Perform/Grow strategy delivering visible margin ramp: 27/31 planned plant closures complete; £15m run-rate savings by mid-2027 with ~£4m benefit in 2026 building further; Perform adds ~100bps by 2028. Core margins rose 30bps to 16.2% in H1 despite variable-pay normalisation 2026-07 interim.
• AI-adjacent tailwinds emerging in Specialist Technologies: Aerospace & Defence organic +25% (LEAP engine, defence backlog), IGT +11% "linked to data centres", plus strong Electronics/semiconductor pull-through. Specialist Technologies (26% margin division) delivered +16.7% organic in H1 2026-07 interim.
• Fortress balance sheet supports ongoing capital return: net debt/EBITDA 0.7x, £127m liquidity, new £80m buyback launched at ~680p VWAP with 1.9m shares already retired H1, plus interim dividend +4.3% 2026-07 interim, 2026-03 FY25.

Key risks (3 bullets)

• Western European Automotive structural weakness persists: -4% in H1 2026 with management "exploring expansion of Optimise scope" for Auto/Industrial regional exposures 2026-07 interim. If deterioration accelerates, further goodwill impairment risk (2024 saw £18m goodwill write-down on NA AGI 2026-03 FY25).
• Cyclical exposure to macro shock: reverse stress test discloses that a 34% H2 26 revenue decline is required to breach covenants — meaning fundamentals resilient, but earnings are cyclical (2020 saw £58m exceptional restructuring) 2026-07 interim, 2024-03 FY23.
• Valuation now demands execution: at 914.5p the stock has run 45% in 12m and 37% in 30 days, likely partially discounting Optimise benefits and any residual bid speculation; recent Apollo approach not proceeding removes near-term takeout support 2026-07 interim; market data.

Operating leverage

Bodycote is a high-fixed-cost, asset-heavy industrial with meaningful but not extreme operating leverage. Fixed-cost base includes ~£268m employee costs, ~£70m utilities, £70m depreciation on ~£478m PP&E, plus lease/central costs — collectively >60% of the cost base has significant fixity relative to short-term volume. Group adjusted EBITDA margin is ~25%. In H1 2026, 3.3% headline revenue growth translated to 10.7% adjusted OP growth (drop-through ~50%); on organic 6.5% the drop-through implies incremental margin ~25-30%. The Optimise programme has retired ~£80m of non-core revenue while preserving physical capacity in the Core network — meaning the group now has notable spare capacity in Precision Heat Treatment sites that recently absorbed transferred volumes at low incremental cost. Illustratively, a 10-20% revenue beat above plan could add £30-70m to operating profit (25-60% uplift) on £114m FY25 base, particularly if it lands in Specialist Technologies (26% margins). Not software-like leverage, but meaningfully positive 2026-07 interim, 2026-03 FY25.

Value-trap signals

None identified as structural. Two-year revenue decline was cyclical (Auto/Industrial destock, prior-year OilGas project loss) not secular; margins held up; balance sheet strengthened; dividend maintained; buybacks executed; no accounting concerns raised by PwC. The North American AGI CGU carrying ~£64m of goodwill remains sensitivity-flagged and is worth monitoring 2026-07 interim.

Earnings vs. expectations

• FY 2023: Adj OP £127.6m, growth 14% at actual FX — strong, beat/met expectations.
• FY 2024: Guidance held during year; delivered adj OP £129m in line with company-compiled consensus after ERP write-down and £18m goodwill impairment on NA AGI. Statutory hit but adjusted result in line.
• FY 2025: May 2025 trading update confirmed "in line with market expectations" (consensus £115.7-123.0m op profit); delivered £114.3m — bottom end of range. Slight disappointment on Oil & Gas headwind.
• H1 2026: "In line with expectations", FY26 outlook unchanged. Consistent delivery.

Pattern: reliable in-line delivery, no profit warnings across the period, management is credible on guidance but rarely upgrades intra-year. Score: 55-60 (mostly in-line, occasional slight miss offset by beat).

Conviction: 4/5 (high)

Anchors: (1) clean disclosure and audited by PwC without qualification; (2) 5-year filing set gives strong visibility across a full cycle including COVID trough, 2023 peak, 2024-25 trough and recovery; (3) multiple valuation approaches converge on £850-1,050p range.

Caveats: (1) end-market cyclicality creates genuine uncertainty around 2027-28 EPS; (2) recent share price move may reflect residual takeover speculation that could unwind.